Ultibro Breezhaler superior to Seretide in reduction of exacerbations in COPD in LANTERN study- Novartis
Novartis has presented new data that demonstrated once-daily Ultibro Breezhaler (indacaterol/glycopyrronium bromide) was superior in reducing exacerbations (flare ups) and improving lung function compared to twice-daily Seretide Accuhaler (salmeterol/fluticasone (SFC)), in patients with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD). These findings from the head-to-head LANTERN study were presented for the first time at the European Respiratory Society (ERS) International Congress, September 6-10, in Munich, Germany.
The LANTERN study showed Ultibro Breezhaler significantly reduced the rate of moderate-to-severe exacerbations by 31% compared to SFC, in moderate-to-severe COPD patients with a history of one exacerbation or none in the previous year. In addition, Ultibro Breezhaler patients had significantly increased lung function (trough FEV1 0.075 L (p<0.001); auc0-4h 0.122 l (p><0.001)), as compared to sfc after 26 weeks of treatment. the safety profile of ultibro breezhaler was comparable to sfc.>0.001)),>0.001);>